Amicure Bioscience

Innovative Drug Development Platform

Advancing Technology, Caring for Companions

About  Amicure

Amicure, as a high-tech company focused on the R&D and innovation of veterinary pharmaceuticals and medical devices. We are dedicated to safeguarding pet health by leveraging cutting-edge technology and profound pharmaceutical R&D capabilities.

Amicure focuses on R&D in innovative veterinary pharmaceuticals, specializing in the research, development, production, and sale of veterinary drugs. With “Integrated Diagnosis & Treatment” and “Personalized Therapy” as our core competencies for competing in international and domestic markets, we aims to provide safe, efficient, and convenient veterinary medications and diagnostic & treatment solutions for pet owners in the Asia-Pacific region and globally.

Leveraging our own R&D and clinical translation strengths, along with the mature pharmaceutical industrial ecosystem of the Greater Bay Area, Amicure aims to become a leading enterprise in the global veterinary drug and device industry.

Learn More

Global Presence, International Team

Our R&D team possesses an international perspective and multidisciplinary educational backgrounds. With simultaneous regulatory submission for marketing approval and industrialization in both China and the US, Amicure has the capability for global market deployment.

Integrated Diagnosis and Treatment

We combine diagnostic services with drug development to improve treatment outcomes and pet owner satisfaction, realizing the concept of personalized pet treatment tailored to the specific condition.

Robust Product R&D Pipeline

We feature an advanced liposomal nanodrug technology platform, innovative small molecule and biotech drug R&D platforms, and an efficient clinical translation platform, covering the entire chain from R&D, clinical trials, registration, to production.

Mission, Vision, Values

Proactive Planning, Bold Exploration

Amicure has strategically invested early in the R&D of companion diagnostic products for pets, actively exploring new diagnostic technologies and methods, aiming to provide more comprehensive and precise diagnostic and treatment services for pets.

Embrace Innovation, Grow Together

In the future, we will continue to increase investment in R&D and clinical translation, continually launching innovative and competitive new products. Meanwhile, we will actively expand into domestic and international markets, seeking in-depth cooperation with pet healthcare institutions in the US, Southeast Asia, and domestically, to jointly promote the development of the veterinary medicine industry.

Relentless Effort, Aspiring to the Top

We firmly believe that through our unremitting efforts and continuous innovation, Amicure will become a leading enterprise in the global veterinary drug and device industry.

Core Team

Guided by the core philosophy of “Advancing Technology, Caring for Companions”, We strive through relentless effort and continuous innovation to provide safe, efficient, and convenient companion animal medications and diagnostic & treatment solutions for pet owners in the Asia-Pacific region and globally.

Innovative Drug Development Platform

Our small molecule drug and biotech drug development platform encompasses the complete process from drug discovery and optimization to preclinical evaluation, ensuring the efficiency and success rate of drug R&D.

N

Small Molecule Compounds

N

Macromolecular Antibody Drugs

Advanced Liposomal Nanotechnology Platform

Liposome technology, as a drug delivery system, can significantly enhance drug bioavailability and targeting, reduce drug side effects, and provide safer and more effective treatment options for pets.

Global Innovation Platform

Pioneering Companion Animal Health

Amicure boasts a professional team composed of renowned drug R&D experts, biologists, and clinical translation specialists from both China and abroad. We will pursue simultaneous regulatory submission for the registration, marketing, and industrialization of innovative veterinary drugs and medical devices in both China and the US. By combining independent R&D with the introduction of internationally advanced technologies, we will continuously launch competitive new products. At the same time, we will actively seek multi-dimensional cooperation with international and domestic pet healthcare institutions in areas such as clinical trials and marketing, to jointly drive the development of the veterinary pharmaceutical industry.

 

Partnership

Industry Insights

The global animal health market is relatively mature and shows a stable growth trend. Driven by factors such as steady global population growth and sustained increase in demand for meat consumption, the global animal health market size is expected to reach USD 55.8 billion by 2026, with a Compound Annual Growth Rate (CAGR) of 5% from 2022 to 2026. While the global animal health market size is expanding, its structure has also undergone significant changes. From the perspective of target animals, the veterinary drug sector is the main source of consumption growth in international markets, accounting for a market share of 40%, i.e., USD 22.3 billion.

Global Animal Health Market Size (USD Billions)

E-mail

ir.marking@amicurebios.com

Address

Room 1811, 18th Floor,Hopewell Centre,23 Harbour Road, Wan Chai
Hong Kong